Literature DB >> 4771846

[Increase of factor VIII-(antihemophilic globulin)-activity in plasma of hemophiliacs following addition of synthetic fibrinolytic compounds].

E von Kaulla, K N von Kaulla.   

Abstract

Mesh：

Substances：

Year:  1973        PMID： 4771846     DOI： 10.1007/bf01468360

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


× No keyword cloud information.
  7 in total

1.  INACTIVATION OF ANTIPLASMIN AND COMPLEMENT C1 IN HUMAN PLASMA RENDERED FIBRINOLYTIC BY SYNTHETIC ORGANIC COMPOUNDS.

Authors:  K N VONKAULLA
Journal:  Thromb Diath Haemorrh       Date:  1963-11-01

2.  Hemophilic syndromes and hemophilia.

Authors:  L M TOCANTINS
Journal:  Blood       Date:  1954-03       Impact factor: 22.113

3.  [In-vitro inhibition of thrombocyte aggregation induced by xenogenic serum].

Authors:  K N von Kaulla; J Gerloff
Journal:  Res Exp Med (Berl)       Date:  1972

4.  Factor VIII (AHF) activity of small size produced by succinylating plasma.

Authors:  E M Barrow; J B Graham
Journal:  Am J Physiol       Date:  1972-01

5.  Production of antihemophilic (factor VIII) activity from albumin.

Authors:  E M Barrow; R H Lester; A M Johnson; J B Graham
Journal:  Am J Physiol       Date:  1972-04

6.  Factor 8 detection by hemagglutination inhibition: hemophilia A and von Willebrand's disease.

Authors:  D P Stites; E J Hershgold; J D Perlman; H H Fudenberg
Journal:  Science       Date:  1971-01-15       Impact factor: 47.728

7.  Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor.

Authors:  T S Zimmerman; O D Ratnoff; A E Powell
Journal:  J Clin Invest       Date:  1971-01       Impact factor: 14.808
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.